The HCPLive Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...
October 25th 2024
New research indicates semaglutide reduced albuminuria and body weight in CKD patients without diabetes, highlighting its potential renal benefits.
Elevating Care for PAH: Applying Recommended Management Approaches to Maximize Outcomes
View More
‘REEL’ Time Patient Counseling™: Navigating the Complex Journey of Diagnosing and Managing Fabry Disease
View More
Expert Illustrations & Commentaries™: Envisioning Novel Therapeutic Approaches to Managing ANCA-associated Vasculitis
View More
Sotatercept Reduces Pulmonary Vascular Resistance in Patients with Pulmonary Arterial Hypertension
April 1st 2021Results of the phase 2 PULSAR trial indicate sotatercept could be an effective adjunct to background medical therapy for reducing pulmonary vascular resistance in patients with pulmonary arterial hypertension.
Inflammatory Diseases Double Mortality Risk in Young Heart Attack Patients
March 31st 2021An analysis of the YOUNG-MI registry suggests patients aged 50 or younger who suffer a heart attack were at nearly twice the risk of mortality if they had a diagnosis of a systemic inflammatory disease, such as rheumatoid arthritis and lupus, when compared to their counterparts without an inflammatory disease.
Long-term Semaglutide Leads to Continued Weight Loss Versus Placebo
March 31st 2021Patients who continued taking semaglutide (Rybelsus/Novo Nordisk) after an initial 20-week therapy period saw continued weight loss, leading to the hope that a new pharmacologic approach to weight loss could be on the horizon.
NYHA Class Less Sensitive than KCCQ-OS for Capturing Heart Failure Progression
March 30th 2021An analysis of the CHAMP-HF registry indicates KCCQ-OS was more sensitive at tracking changes in disease state among heart failure patients, indicating the importance of including patient-reported outcome measures in heart failure management.
Adverse Pregnancy Outcomes and Cardiovascular Disease Risk in Women with Nisha Parikh, MD
March 29th 2021The American Heart Association is highlighting the effect of adverse pregnancy outcomes on risk of cardiovascular disease later in life among women. Check out this interview with the chair of the writing committee for more perspective on the statement.
Medtronic's Harmony TPV System Receives Historic FDA Approval for Congenital Heart Disease
March 26th 2021The FDA announced approval for the Harmony Transcatheter Pulmonary Valve device for treatment of patients with native or surgically-repaired right ventricular outflow tract was awarded to Medtronic Inc.
Transgender Youth at Risk of Adverse Cardiometabolic Health, ENDO 2021 Study Finds
March 22nd 2021An analysis comparing propensity-matched data from 4k transgender is providing an updated overview of the risk profile for patients undergoing gender-affirming therapy compared to their cisgender counterparts.